Cyclacel Pharmaceuticals Stock Current Ratio

CYCC Stock  USD 1.96  0.04  2.08%   
Cyclacel Pharmaceuticals fundamentals help investors to digest information that contributes to Cyclacel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cyclacel Stock. The fundamental analysis module provides a way to measure Cyclacel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclacel Pharmaceuticals stock.
As of March 28, 2024, Current Ratio is expected to decline to 0.87.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cyclacel Current Ratio Analysis

Cyclacel Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Cyclacel Pharmaceuticals Current Ratio

0.87

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Cyclacel Pharmaceuticals Current Ratio

    
  6.38 X  
Most of Cyclacel Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclacel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cyclacel Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Cyclacel Pharmaceuticals is extremely important. It helps to project a fair market value of Cyclacel Stock properly, considering its historical fundamentals such as Current Ratio. Since Cyclacel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclacel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclacel Pharmaceuticals' interrelated accounts and indicators.
0.570.230.150.010.02-0.06-0.31-0.69-0.320.09-0.040.930.110.09-0.060.20.150.65-0.260.920.90.09
0.57-0.53-0.720.72-0.80.210.55-0.980.02-0.3-0.10.82-0.740.020.00.06-0.710.270.080.570.560.01
0.23-0.530.83-0.930.8-0.2-0.90.37-0.40.61-0.21-0.040.85-0.24-0.47-0.070.860.27-0.730.240.29-0.24
0.15-0.720.83-0.850.97-0.42-0.950.6-0.360.430.03-0.210.990.02-0.020.00.980.2-0.280.090.10.03
0.010.72-0.93-0.85-0.880.210.82-0.590.35-0.570.140.3-0.870.220.340.06-0.88-0.220.630.02-0.010.22
0.02-0.80.80.97-0.88-0.3-0.870.69-0.260.420.09-0.330.970.04-0.010.090.970.18-0.27-0.06-0.050.04
-0.060.21-0.2-0.420.21-0.30.44-0.250.57-0.050.360.1-0.440.22-0.210.68-0.340.13-0.12-0.06-0.080.22
-0.310.55-0.9-0.950.82-0.870.44-0.410.46-0.450.070.02-0.950.030.20.08-0.93-0.20.47-0.31-0.330.03
-0.69-0.980.370.6-0.590.69-0.25-0.410.020.180.1-0.910.62-0.010.11-0.120.59-0.390.06-0.69-0.68-0.01
-0.320.02-0.4-0.360.35-0.260.570.460.02-0.280.26-0.18-0.380.17-0.180.47-0.3-0.30.26-0.41-0.430.17
0.09-0.30.610.43-0.570.42-0.05-0.450.18-0.280.03-0.050.44-0.09-0.240.10.450.27-0.440.090.11-0.1
-0.04-0.1-0.210.030.140.090.360.070.10.260.03-0.08-0.060.960.330.75-0.02-0.220.24-0.14-0.210.96
0.930.82-0.04-0.210.3-0.330.10.02-0.91-0.18-0.05-0.08-0.240.05-0.110.18-0.20.57-0.190.880.860.05
0.11-0.740.850.99-0.870.97-0.44-0.950.62-0.380.44-0.06-0.24-0.07-0.07-0.080.980.19-0.310.060.08-0.07
0.090.02-0.240.020.220.040.220.03-0.010.17-0.090.960.05-0.070.330.67-0.05-0.270.240.02-0.051.0
-0.060.0-0.47-0.020.34-0.01-0.210.20.11-0.18-0.240.33-0.11-0.070.330.11-0.10.090.77-0.15-0.210.34
0.20.06-0.070.00.060.090.680.08-0.120.470.10.750.18-0.080.670.110.030.140.00.070.010.67
0.15-0.710.860.98-0.880.97-0.34-0.930.59-0.30.45-0.02-0.20.98-0.05-0.10.030.22-0.350.060.08-0.05
0.650.270.270.2-0.220.180.13-0.2-0.39-0.30.27-0.220.570.19-0.270.090.140.22-0.150.590.58-0.27
-0.260.08-0.73-0.280.63-0.27-0.120.470.060.26-0.440.24-0.19-0.310.240.770.0-0.35-0.15-0.33-0.380.24
0.920.570.240.090.02-0.06-0.06-0.31-0.69-0.410.09-0.140.880.060.02-0.150.070.060.59-0.331.00.02
0.90.560.290.1-0.01-0.05-0.08-0.33-0.68-0.430.11-0.210.860.08-0.05-0.210.010.080.58-0.381.0-0.06
0.090.01-0.240.030.220.040.220.03-0.010.17-0.10.960.05-0.071.00.340.67-0.05-0.270.240.02-0.06
Click cells to compare fundamentals

Cyclacel Current Ratio Historical Pattern

Today, most investors in Cyclacel Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclacel Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclacel Pharmaceuticals current ratio as a starting point in their analysis.
   Cyclacel Pharmaceuticals Current Ratio   
       Timeline  
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

Cyclacel Discontinued Operations

Discontinued Operations

30,400

At present, Cyclacel Pharmaceuticals' Discontinued Operations is projected to decrease significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Cyclacel Pharmaceuticals has a Current Ratio of 6.38 times. This is 119.24% higher than that of the Biotechnology sector and 8.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 195.37% lower than that of the firm.

Cyclacel Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclacel Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclacel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics of similar companies.
Cyclacel Pharmaceuticals is currently under evaluation in current ratio category among related companies.

Cyclacel Fundamentals

About Cyclacel Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cyclacel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclacel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Current Ratio 0.91  0.87 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cyclacel Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cyclacel Pharmaceuticals' short interest history, or implied volatility extrapolated from Cyclacel Pharmaceuticals options trading.

Pair Trading with Cyclacel Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:
Check out Cyclacel Pharmaceuticals Piotroski F Score and Cyclacel Pharmaceuticals Altman Z Score analysis.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(26.75)
Revenue Per Share
0.494
Return On Assets
(0.86)
Return On Equity
(2.73)
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.